Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.76
+2.9%
$1.21
$0.56
▼
$2.72
$154.25M1.7127.65 million shs7.70 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.41
-0.5%
$28.82
$23.62
▼
$31.44
$164.50B0.3136.19 million shs38.28 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+2.92%+23.08%+121.30%+49.15%-1.12%
Pfizer Inc. stock logo
PFE
Pfizer
-0.55%-5.10%-8.24%-2.10%+9.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.76
+2.9%
$1.21
$0.56
▼
$2.72
$154.25M1.7127.65 million shs7.70 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.41
-0.5%
$28.82
$23.62
▼
$31.44
$164.50B0.3136.19 million shs38.28 million shs
7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+2.92%+23.08%+121.30%+49.15%-1.12%
Pfizer Inc. stock logo
PFE
Pfizer
-0.55%-5.10%-8.24%-2.10%+9.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$6.33259.85% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.18
Hold$30.3210.59% Upside

Current Analyst Ratings Breakdown

Latest PFE and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingMarket Perform$29.00
11/12/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$5.00
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingSell (E+)
11/11/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingOverweight$8.00 ➝ $6.00
11/9/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C) ➝ Hold (C+)
11/6/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Reiterated RatingBuy$3.00 ➝ $8.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
Set Price Target$34.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetBuy$33.00 ➝ $34.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeBuy ➝ Hold
11/5/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetBuy$31.00 ➝ $33.00
11/4/2026
Pfizer Inc. stock logo
PFE
Pfizer
Set Price Target$40.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K3,231.95N/AN/A($0.31) per share-5.68
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.50$4.18 per share6.56$15.67 per share1.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$0.54N/AN/AN/AN/A-28,886.30%-75.67%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7039.169.261.906.34%19.88%8.52%2/2/2027 (Estimated)

Latest PFE and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.2067-$0.50-$0.2933-$0.50$2.27 million$0.30 million
11/3/2026Q3 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7350$0.87+$0.1350$0.56$15.85 billion$16.58 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.27%-13.20%245.71%16 Years

Latest PFE and INO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.435.85%11/6/202611/6/202612/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
0.57
0.57
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.42
1.10

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
112110.18 million108.31 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer: Struggling To Meet Dividend Beyond 2027
Pfizer near-term support and resistance levels
Pfizer Advances RSV Booster Study in Older Adults
Pfizer Is Shopping for China’s Biotech Breakthroughs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.76 +0.05 (+2.92%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.84 +0.08 (+4.26%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Pfizer stock logo

Pfizer NYSE:PFE

$27.41 -0.13 (-0.46%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$27.44 +0.02 (+0.08%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.